Ipilimumab plus nivolumab for advanced melanoma

Affiliations

¹ Department of Dermatology and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg 69120, Germany. Electronic address: jessica.hassel@med.uni-heidelberg.de.

Comment

Jessica C Hassel. Lancet Oncol. 2016 Nov.

. 2016 Nov;17(11):1471-1472.

doi: 10.1016/S1470-2045(16)30409-0. Epub 2016 Sep 8.

¹ Department of Dermatology and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg 69120, Germany. Electronic address: jessica.hassel@med.uni-heidelberg.de.

No abstract available

Comment on

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor DR, Salama AK, Taylor MH, Ott PA, Horak C, Gagnier P, Jiang J, Wolchok JD, Postow MA. Hodi FS, et al. Lancet Oncol. 2016 Nov;17(11):1558-1568. doi: 10.1016/S1470-2045(16)30366-7. Epub 2016 Sep 9. Lancet Oncol. 2016. PMID: 27622997 Free PMC article. Clinical Trial.